Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.

[1]  M. Ruscica,et al.  Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study , 2020, European journal of preventive cardiology.

[2]  G. Kolovou,et al.  Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia , 2020, European journal of preventive cardiology.

[3]  Deepak L. Bhatt,et al.  Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics , 2019, European heart journal.

[4]  J. Jukema,et al.  Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S] , 2019, Journal of Lipid Research.

[5]  R. Hegele,et al.  Familial chylomicronemia syndrome: an under‐recognized cause of severe hypertriglyceridaemia , 2019, Journal of internal medicine.

[6]  M. Pencina,et al.  Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. , 2019, JAMA cardiology.

[7]  G. Watts,et al.  A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES. , 2019, Pharmacological research.

[8]  S. Nissen,et al.  Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease , 2019, European journal of preventive cardiology.

[9]  C. Packard.  Triglyceride lowering 2.0: back to the future? , 2019, European heart journal.

[10]  J. Trauger,et al.  A lipoprotein lipase–GPI-anchored high-density lipoprotein–binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome , 2019, The Journal of Biological Chemistry.

[11]  R. Giugliano,et al.  Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. , 2019, Circulation.

[12]  K. Musunuru,et al.  Angiopoietin-Like 3 , 2019, JACC. Basic to translational science.

[13]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[14]  M. R. Kim,et al.  Antiinflammatory activity of ANGPTL4 facilitates macrophage polarization to induce cardiac repair. , 2019, JCI insight.

[15]  D. Gaudet,et al.  Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. , 2019, The New England journal of medicine.

[16]  M. Jauhiainen,et al.  Short-Term Cooling Increases Plasma ANGPTL3 and ANGPTL8 in Young Healthy Lean Men but Not in Middle-Aged Men with Overweight and Prediabetes , 2019, Journal of clinical medicine.

[17]  Zongwei Wang,et al.  Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism , 2019, BioMed research international.

[18]  W. Sasiela,et al.  Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia , 2019, Circulation.

[19]  P. Libby,et al.  The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential , 2019, Cardiovascular Diabetology.

[20]  Deepak L. Bhatt,et al.  Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. , 2019, Journal of the American College of Cardiology.

[21]  S. Kersten.  New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk , 2019, Current opinion in lipidology.

[22]  Thomas M. Smith,et al.  Structure of lipoprotein lipase in complex with GPIHBP1 , 2019, Proceedings of the National Academy of Sciences.

[23]  S. Yamashita,et al.  Recent advances in synthetic pharmacotherapies for dyslipidaemias , 2019, European journal of preventive cardiology.

[24]  S. Bertolini,et al.  Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia , 2019, Journal of biomedical research.

[25]  V. Ranzani,et al.  PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients[S] , 2019, Journal of Lipid Research.

[26]  Deepak L. Bhatt,et al.  Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease , 2019, JAMA.

[27]  M. Ploug,et al.  On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity , 2019, Journal of Lipid Research.

[28]  M. Ruscica,et al.  Deciphering the role of V200A and N291S mutations leading to LPL deficiency. , 2019, Atherosclerosis.

[29]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[30]  S. Virani,et al.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. , 2018, Endocrine reviews.

[31]  N. Ferri,et al.  Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects , 2018, Journal of cardiovascular development and disease.

[32]  Alexander E. Lopez,et al.  Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes , 2018, Nature Communications.

[33]  W. Cromwell,et al.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding , 2018, Journal of Lipid Research.

[34]  C. Sirtori,et al.  PPAR Agonists and Metabolic Syndrome: An Established Role? , 2018, International journal of molecular sciences.

[35]  T. Horvath,et al.  Brown adipose tissue derived ANGPTL4 controls glucose and lipid metabolism and regulates thermogenesis , 2018, Molecular metabolism.

[36]  Kiran Musunuru,et al.  Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3. , 2018, Circulation.

[37]  C. Sirtori,et al.  Present therapeutic role of cholesteryl ester transfer protein inhibitors , 2018, Pharmacological research.

[38]  Jonathan C. Cohen,et al.  Increased thermogenesis by a noncanonical pathway in ANGPTL3/8-deficient mice , 2018, Proceedings of the National Academy of Sciences.

[39]  M. Alves-Bezerra,et al.  Triglyceride Metabolism in the Liver. , 2017, Comprehensive Physiology.

[40]  A. Gotto,et al.  Effect of fibrates on glycemic parameters: A systematic review and meta‐analysis of randomized placebo‐controlled trials , 2017, Pharmacological research.

[41]  D. Gaudet,et al.  ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. , 2017, The New England journal of medicine.

[42]  S. Shetty,et al.  ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase , 2017, Molecular metabolism.

[43]  Ying-Mei Feng,et al.  Angiopoietin‐Like Protein 4 Is a High‐Density Lipoprotein (HDL) Component for HDL Metabolism and Function in Nondiabetic Participants and Type‐2 Diabetic Patients , 2017, Journal of the American Heart Association.

[44]  Jonathan C. Cohen,et al.  ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S] , 2017, Journal of Lipid Research.

[45]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[46]  Richard G. Lee,et al.  Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides , 2017, The New England journal of medicine.

[47]  C. Sirtori,et al.  PPAR-α agonists are still on the rise: an update on clinical and experimental findings , 2017, Expert opinion on investigational drugs.

[48]  S. Young,et al.  Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia , 2017, The New England journal of medicine.

[49]  Daniel R. Lavage,et al.  Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease , 2017, JAMA.

[50]  Stanley T Crooke,et al.  Cellular uptake and trafficking of antisense oligonucleotides , 2017, Nature Biotechnology.

[51]  S. Tsimikas.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. , 2017, Journal of the American College of Cardiology.

[52]  A. Murphy,et al.  Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition , 2017, Proceedings of the National Academy of Sciences.

[53]  S. Young,et al.  Mobility of “HSPG-bound” LPL explains how LPL is able to reach GPIHBP1 on capillaries[S] , 2016, Journal of Lipid Research.

[54]  Fabin Dang,et al.  Fasting and Feeding Signals Control the Oscillatory Expression of Angptl8 to Modulate Lipid Metabolism , 2016, Scientific Reports.

[55]  W. Sasiela,et al.  Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3 , 2016 .

[56]  Li Wei,et al.  Angiopoietin-like protein 4 improves glucose tolerance and insulin resistance but induces liver steatosis in high-fat-diet mice. , 2016, Molecular medicine reports.

[57]  D. Gudbjartsson,et al.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.

[58]  Amnah Siddiqa,et al.  Structural characterization of ANGPTL8 (betatrophin) with its interacting partner lipoprotein lipase , 2016, Comput. Biol. Chem..

[59]  Dermot F. Reilly,et al.  Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .

[60]  S. Booten,et al.  Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes. , 2016, Journal of medicinal chemistry.

[61]  Alexander E. Lopez,et al.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.

[62]  S. Young,et al.  The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain , 2016, eLife.

[63]  A. Abou-Samra,et al.  A lipasin/Angptl8 monoclonal antibody lowers mouse serum triglycerides involving increased postprandial activity of the cardiac lipoprotein lipase , 2015, Scientific Reports.

[64]  W. D. van Marken Lichtenbelt,et al.  ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure , 2015, eLife.

[65]  S. E. Park,et al.  AMP-activated protein kinase suppresses the expression of LXR/SREBP-1 signaling-induced ANGPTL8 in HepG2 cells , 2015, Molecular and Cellular Endocrinology.

[66]  Jonathan C. Cohen,et al.  Hepatic ANGPTL3 regulates adipose tissue energy homeostasis , 2015, Proceedings of the National Academy of Sciences.

[67]  D. Gaudet,et al.  Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. , 2015, The New England journal of medicine.

[68]  Jonathan C. Cohen,et al.  Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion1[S] , 2015, Journal of Lipid Research.

[69]  Jonathan C. Cohen,et al.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys1[S] , 2015, Journal of Lipid Research.

[70]  X. Zha,et al.  A vital role for Angptl3 in the PAN-induced podocyte loss by affecting detachment and apoptosis in vitro , 2015, BMC Nephrology.

[71]  K. Bornfeldt,et al.  GPIHBP1: two get tangled. , 2015, Circulation research.

[72]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[73]  N. Tan,et al.  Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise , 2014, Proceedings of the National Academy of Sciences.

[74]  F. Sacks,et al.  Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. , 2014, JAMA internal medicine.

[75]  X. Zha,et al.  Angiopoietin-Like 3 Induces Podocyte F-Actin Rearrangement through Integrin α V β 3/FAK/PI3K Pathway-Mediated Rac1 Activation , 2013, BioMed research international.

[76]  G. Watts,et al.  Demystifying the management of hypertriglyceridaemia , 2013, Nature Reviews Cardiology.

[77]  E. Poggiogalle,et al.  Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis. , 2013, International journal of cardiology.

[78]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[79]  A. Prat,et al.  Furin Is the Primary in Vivo Convertase of Angiopoietin-like 3 and Endothelial Lipase in Hepatocytes* , 2013, The Journal of Biological Chemistry.

[80]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[81]  S. Young,et al.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis. , 2013, Genes & development.

[82]  Jonathan C. Cohen,et al.  Atypical angiopoietin-like protein that regulates ANGPTL3 , 2012, Proceedings of the National Academy of Sciences.

[83]  Ren Zhang,et al.  Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. , 2012, Biochemical and biophysical research communications.

[84]  Ji Young Kim,et al.  Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. , 2012, American journal of physiology. Endocrinology and metabolism.

[85]  Pengcheng Zhu,et al.  Angiopoietin-like 4: a decade of research. , 2012, Bioscience reports.

[86]  G. Labbadia,et al.  Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. , 2012, The Journal of clinical endocrinology and metabolism.

[87]  Sander Kersten,et al.  Regulation of triglyceride metabolism by Angiopoietin-like proteins. , 2012, Biochimica et biophysica acta.

[88]  S. Kathiresan,et al.  Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[89]  G. Franceschini,et al.  Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3 , 2012, Circulation. Cardiovascular genetics.

[90]  Anna Zhou,et al.  Angiopoietin-like 4 (Angptl4) Protein Is a Physiological Mediator of Intracellular Lipolysis in Murine Adipocytes* , 2012, The Journal of Biological Chemistry.

[91]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[92]  Jonathan C. Cohen,et al.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.

[93]  N. Tan,et al.  Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. , 2010, Cell metabolism.

[94]  S. Young,et al.  GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. , 2010, Cell metabolism.

[95]  D. Rader,et al.  Angiopoietin-like Protein 3 Inhibits Lipoprotein Lipase Activity through Enhancing Its Cleavage by Proprotein Convertases* , 2010, The Journal of Biological Chemistry.

[96]  T. Miida,et al.  Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events , 2010, Current opinion in lipidology.

[97]  Y. Hu,et al.  GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4 , 2009, Journal of Lipid Research.

[98]  Robert V Farese,et al.  Angiopoietin-like 4 (ANGPTL4, Fasting-induced Adipose Factor) Is a Direct Glucocorticoid Receptor Target and Participates in Glucocorticoid-regulated Triglyceride Metabolism* , 2009, The Journal of Biological Chemistry.

[99]  P. Parren,et al.  Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo , 2009, Nature Biotechnology.

[100]  H. Hendriks,et al.  Caloric Restriction and Exercise Increase Plasma ANGPTL4 Levels in Humans via Elevated Free Fatty Acids , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[101]  J. Romijn,et al.  Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. , 2009, Biochimica et biophysica acta.

[102]  Y. Hu,et al.  Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL) , 2009, Journal of Biological Chemistry.

[103]  Jonathan C. Cohen,et al.  Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function , 2009, Journal of Biological Chemistry.

[104]  A. Xu,et al.  A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme Dimerization* , 2009, Journal of Biological Chemistry.

[105]  F. Schick,et al.  Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator–Activated Receptor (PPAR)-δ and Is of Metabolic Relevance in Humans , 2009, Diabetes.

[106]  Eric Boerwinkle,et al.  Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. , 2008, The Journal of clinical investigation.

[107]  W. Guo,et al.  Angiopoietin-like protein 3 modulates barrier properties of human glomerular endothelial cells through a possible signaling pathway involving phosphatidylinositol-3 kinase/protein kinase B and integrin αVβ3 , 2008 .

[108]  S. Young,et al.  GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons , 2007, Current opinion in lipidology.

[109]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[110]  D. Powell,et al.  Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice , 2007, Proceedings of the National Academy of Sciences.

[111]  S. Young,et al.  Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. , 2007, Cell metabolism.

[112]  Eric Boerwinkle,et al.  Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL , 2007, Nature Genetics.

[113]  M. Matsuda,et al.  Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[114]  T. Olivecrona,et al.  Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue , 2006, Proceedings of the National Academy of Sciences.

[115]  Jacques Samarut,et al.  The Lipoprotein Lipase Inhibitor ANGPTL3 Is Negatively Regulated by Thyroid Hormone* , 2006, Journal of Biological Chemistry.

[116]  W. Wahli,et al.  The Fasting-induced Adipose Factor/Angiopoietin-like Protein 4 Is Physically Associated with Lipoproteins and Governs Plasma Lipid Levels and Adiposity* , 2006, Journal of Biological Chemistry.

[117]  S. M. Park,et al.  Apolipoprotein C-II is a novel substrate for matrix metalloproteinases. , 2006, Biochemical and biophysical research communications.

[118]  C. Fraser,et al.  Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. , 2005, Endocrinology.

[119]  J. Cha,et al.  Differential regulation and properties of angiopoietin-like proteins 3 and 4 Published, JLR Papers in Press, May 1, 2005. DOI 10.1194/jlr.M500005-JLR200 , 2005, Journal of Lipid Research.

[120]  Kok Weng Chan,et al.  Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[121]  Kenny K. Wong,et al.  Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Guoqing Yang,et al.  Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4 Published, JLR Papers in Press, August 1, 2004. DOI 10.1194/jlr.M400138-JLR200 , 2004, Journal of Lipid Research.

[123]  M. Matsuda,et al.  Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor. , 2004, Biochemical and biophysical research communications.

[124]  H. Katagiri,et al.  ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. , 2004, Biochemical and biophysical research communications.

[125]  Kenichi Yoshida,et al.  Protein Region Important for Regulation of Lipid Metabolism in Angiopoietin-like 3 (ANGPTL3) , 2003, Journal of Biological Chemistry.

[126]  M. Matsuda,et al.  Angiopoietin-like Protein 3 Mediates Hypertriglyceridemia Induced by the Liver X Receptor* , 2003, Journal of Biological Chemistry.

[127]  Takashi Suzuki,et al.  Expression Cloning and Characterization of a Novel Glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding Protein, GPI-HBP1* , 2003, The Journal of Biological Chemistry.

[128]  M. Matsuda,et al.  Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. , 2003, Biochemical and biophysical research communications.

[129]  Theresa Zhang,et al.  Regulation of the angiopoietin-like protein 3 gene by LXR Published, JLR Papers in Press, October 16, 2002. DOI 10.1194/jlr.M200367-JLR200 , 2003, Journal of Lipid Research.

[130]  D. Ramji,et al.  Lipoprotein lipase: structure, function, regulation, and role in disease , 2002, Journal of Molecular Medicine.

[131]  Kenichi Yoshida,et al.  ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase* , 2002, The Journal of Biological Chemistry.

[132]  D. Ramji,et al.  The pivotal role of lipoprotein lipase in atherosclerosis. , 2002, Cardiovascular research.

[133]  D. Rader,et al.  Characterization of the lipolytic activity of endothelial lipase. , 2002, Journal of lipid research.

[134]  G. Camenisch,et al.  ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * , 2002, The Journal of Biological Chemistry.

[135]  T. Fujiwara,et al.  Angptl3 regulates lipid metabolism in mice , 2002, Nature Genetics.

[136]  D. Mangelsdorf,et al.  Regulation of Lipoprotein Lipase by the Oxysterol Receptors, LXRα and LXRβ* , 2001, The Journal of Biological Chemistry.

[137]  P. Chambon,et al.  Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene* , 2000, The Journal of Biological Chemistry.

[138]  B. Spiegelman,et al.  Peroxisome Proliferator-Activated Receptor γ Target Gene Encoding a Novel Angiopoietin-Related Protein Associated with Adipose Differentiation , 2000, Molecular and Cellular Biology.

[139]  Hong-Hee Kim,et al.  Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis , 2000 .

[140]  S. Wattler,et al.  Identification of a mammalian angiopoietin-related protein expressed specifically in liver. , 1999, Genomics.

[141]  D. Rader,et al.  A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.

[142]  L. Havekes,et al.  Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[143]  G. Jensen,et al.  Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. , 1997, Circulation.

[144]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[145]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[146]  Chad A. Cowan,et al.  Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. , 2018, Atherosclerosis.

[147]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[148]  Soo-Ho Choi,et al.  Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. , 2010, Sub-cellular biochemistry.

[149]  D. Tanné,et al.  Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). , 2009, The American journal of cardiology.

[150]  Yosuke Ando,et al.  Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. , 2006, Experimental animals.